### ABOUT XYZAL® ALLERGY 24HR

**Designed to Be Different**

**XYZAL**

**POTENT H1 BLOCKER**

**2X GREATER BINDING AFFINITY THAN ZYRTEC**

The clinical relevance of this finding is unknown.

---

**XYZAL® ALLERGY 24HR**

**True 24-Hour Relief That Doesn’t Fade**

**XYZAL® ALLERGY 24HR**

**POTENT H1 BLOCKER**

**2X GREATER BINDING AFFINITY THAN ZYRTEC**

The clinical relevance of this finding is unknown.

---

### Significant 24-Hour relief with Xyzal *(P<0.001)*:

reduction in major symptom complex score (MSCS)

<table>
<thead>
<tr>
<th>Hours After Drug Intake</th>
<th>Mean Score (MSCS)</th>
</tr>
</thead>
<tbody>
<tr>
<td>-2</td>
<td>14</td>
</tr>
<tr>
<td>-1</td>
<td>12</td>
</tr>
<tr>
<td>0</td>
<td>10</td>
</tr>
<tr>
<td>1</td>
<td>8</td>
</tr>
<tr>
<td>2</td>
<td>6</td>
</tr>
<tr>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td>5</td>
<td>0</td>
</tr>
</tbody>
</table>

- **Xyzal 5 mg (P<0.001)**
- **Placebo**

A double-blind, randomized, placebo-controlled, three-way cross-over study evaluating one dose of levocetirizine 5 mg vs fexofenadine 120 mg and placebo over 28 hours in patients (N=94) with seasonal allergic rhinitis.

**At hour 1, a 34% reduction in symptom score** was demonstrated with Xyzal (n=240), vs 18% with placebo (n=95); and at hour 24 a 46% reduction was demonstrated with Xyzal (n=236), vs 11% with placebo (n=93) *(P<0.001)*.

---

**XYZAL® ALLERGY 24HR**

**Designed to Be Different**

**XYZAL contains the active enantiomer of Zyrtec® with no dextrocetirizine**

- Levocetirizine is the active enantiomer thought to provide the efficacy of Zyrtec
- Dextrocetirizine has a 5.5x higher distribution across the blood-brain barrier than levocetirizine

The clinical relevance regarding the absence of dextrocetirizine is unknown.

---

**XYZAL® ALLERGY 24HR**

**Designed to Be Different**

**XYZAL contains the active enantiomer of Zyrtec® with no dextrocetirizine**

- Levocetirizine is the active enantiomer thought to provide the efficacy of Zyrtec
- Dextrocetirizine has a 5.5x higher distribution across the blood-brain barrier than levocetirizine

The clinical relevance regarding the absence of dextrocetirizine is unknown.

---

**XYZAL® ALLERGY 24HR**

**Designed to Be Different**

**XYZAL contains the active enantiomer of Zyrtec® with no dextrocetirizine**

- Levocetirizine is the active enantiomer thought to provide the efficacy of Zyrtec
- Dextrocetirizine has a 5.5x higher distribution across the blood-brain barrier than levocetirizine

The clinical relevance regarding the absence of dextrocetirizine is unknown.
Significant improvement in overall QOL and all composite scores ($P<0.001$): reduction (improvement) from baseline in RQLQ scores

Phase 3, randomized, double-blind, placebo-controlled, parallel-group study of Xyzal 5 mg vs placebo in 580 US adults (aged 18-65 years) with seasonal allergic rhinitis evaluated improvement of symptoms and health-related quality of life.

Recommend Xyzal® Allergy 24HR for your allergy sufferers.